$CGEM

Cullinan Therapeutics (NASDAQ: CGEN) is set to report Q3 earnings, with analysts expecting a loss of $0.84 per share on zero revenue. The company's stock has surged 134% from its 52-week low, driven by anticipation around its cancer therapy zipalertinib. All 12 analysts rate it a Strong Buy, with a consensus price target of $34.60, implying 120% upside. Investors will watch for updates on the rolling New Drug Application submission for zipalertinib and the company's cash runway.

Cullinan Therapeutics (CGEM) will present data on its T cell engager programs at the ASH meeting, including updated Phase 1 data for CLN-049 in relapsed/refractory AML, showing anti-leukemic activity and a safety profile. The company also has trials in progress for CLN-049 combinations and velinotamig in autoimmune diseases. CLN-049 has FDA Orphan Drug and Fast Track designations.

Cullinan Therapeutics, Inc. (CGEM) filed an SEC Form 8-K — Other Events. Exhibit 99.1 Cullinan Therapeutics Announces Presentations for CLN-049, a FLT3 T Cell Engager, and Velinotamig, a BCMA T Cell Engager, at the 68 th ASH Annual Meeting CAMBRIDGE, Mass., Nov. 04, 2026 (GLOBE NEWSWIRE) -- Cullinan Therapeutics, Inc. (Nasdaq: CGEM), a clinical-stage

Taiho Oncology and Cullinan Therapeutics (CGEM) reported that zipalertinib, an experimental lung cancer drug, showed clinically meaningful intracranial antitumor activity in a Phase 2b trial. Among 43 patients, it achieved a 67.4% intracranial objective response rate. The drug is being evaluated for NSCLC with EGFR mutations and active CNS metastases. Results will be presented at ESMO Congress 2026.

Cullinan Therapeutics (CGEM) dosed the first patient in a Phase 2 study of CLN-049, a treatment for relapsed/refractory AML. The study aims to evaluate the drug's safety and efficacy, with updates expected in December. CLN-049 has received Orphan Drug and Fast Track designations from the FDA.

Analysts maintained Buy ratings on Monte Rosa Therapeutics (GLUE) and Cullinan Management (CGEM). GLUE has a $28.17 avg. price target (147.1% upside), while CGEM has a $35.70 target (141.9% upside). Both have Strong Buy consensus.

H.C. Wainwright reiterated a Buy rating and $35 price target for Cullinan Oncology (CGEM) after its rolling NDA submission for zipalertinib. The stock is up 153% over a year, trading at $14.53. Positive Phase 3 trial results showed improved outcomes for zipalertinib plus chemotherapy in NSCLC. Approval could trigger milestone payments. CGEM has strong cash position but high annual burn rate.

HC Wainwright reiterated a Buy rating on Cullinan Therapeutics with a $35 price target, implying 140.9% upside from the Oct 1 close. The firm cited strong clinical data for zipalertinib, including a 65% overall response rate, and potential milestone payments of $100 million upon approval.

Cullinan Therapeutics (CGEM) initiated an FDA filing for zipalertinib, a lung cancer drug, in combination with chemotherapy. The Phase 3 trial met its primary endpoint, showing improved progression-free survival. The company expects to complete the NDA submission by year-end 2026 and could receive $130 million in milestones upon approvals. Zipalertinib is being developed with Taiho Oncology and Taiho Pharmaceutical.

Cullinan Therapeutics (CGEM) initiated NDA submission for zipalertinib plus chemotherapy in first-line EGFR exon20ins NSCLC under FDA's RTOR program, with completion expected by year-end 2026. The submission follows positive Phase 3 REZILIENT3 trial results, showing significant improvement in progression-free survival. Zipalertinib has FDA Breakthrough Therapy designation, and Cullinan may receive $100M in milestone payments upon approval.